673 related articles for article (PubMed ID: 10081701)
1. Intermittent complete androgen blockade in metastatic prostate cancer.
Rambeaud JJ
Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
[TBL] [Abstract][Full Text] [Related]
2. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
Rambeaud J
Eur Urol; 1998 Dec; 35 Suppl S1():32-36. PubMed ID: 9858850
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
4. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
5. Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.
Goldenberg SL; Gleave ME; Taylor D; Bruchovsky N
Mol Urol; 1999; 3(3):287-292. PubMed ID: 10851335
[TBL] [Abstract][Full Text] [Related]
6. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
7. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
8. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
9. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
10. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
Goldenberg SL; Bruchovsky N; Gleave ME; Sullivan LD; Akakura K
Urology; 1995 May; 45(5):839-44; discussion 844-5. PubMed ID: 7538246
[TBL] [Abstract][Full Text] [Related]
12. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.
Bruchovsky N; Klotz LH; Sadar M; Crook JM; Hoffart D; Godwin L; Warkentin M; Gleave ME; Goldenberg SL
Mol Urol; 2000; 4(3):191-9;discussion 201. PubMed ID: 11062374
[TBL] [Abstract][Full Text] [Related]
13. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer.
Youssef E; Tekyi-Mensah S; Hart K; Bolton S; Forman J
Am J Clin Oncol; 2003 Oct; 26(5):e119-23. PubMed ID: 14528085
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
16. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
[TBL] [Abstract][Full Text] [Related]
17. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
18. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
19. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
Gleave M; Klotz L; Taneja SS
Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]